Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
32 studies found for:    E2609
Show Display Options
Rank Status Study
1 Completed Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: Placebo
2 Completed An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
Condition: Metabolism and Elimination
Intervention: Drug: E2609
3 Completed Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects
Condition: Healthy
Interventions: Drug: E2609;   Drug: Placebo
4 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
5 Recruiting A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
Condition: Healthy Subjects
Interventions: Drug: Placebo;   Drug: E2609;   Drug: Moxifloxacin
6 Completed A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: itraconazole;   Drug: rifampin;   Drug: digoxin;   Drug: donepezil
7 Completed An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
Condition: Alzheimer's Disease
Intervention: Drug: E2609
8 Recruiting Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease
Conditions: Alzheimer Disease;   Dementia, Alzheimer Type
Interventions: Drug: E2609;   Drug: Placebo
9 Completed Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
Condition: Alzheimer's Disease
Interventions: Drug: Drug: E2609;   Drug: Placebo
10 Completed
Has Results
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin;   Drug: Placebo: tablet of Rivaroxaban;   Drug: Placebo: syringes of Enoxaparin
11 Completed
Has Results
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: adalimumab;   Drug: methotrexate;   Biological: placebo
12 Completed Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
Conditions: Prevention;   Venous Thromboembolism
Interventions: Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
13 Completed
Has Results
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept;   Drug: Placebo
14 Completed Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
15 Recruiting Glutamate, Hyperarousal and Restless Legs Syndrome
Condition: Restless Legs Syndrome
Intervention:
16 Completed An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Condition: Rheumatoid Arthritis
Intervention:
17 Recruiting Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly;   Drug: Placebo
18 Completed
Has Results
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Condition: Rheumatoid Arthritis
Interventions: Drug: Tocilizumab;   Drug: Disease-modifying anti-rheumatic drugs;   Drug: Non-steroidal anti-inflammatory drugs;   Drug: Oral corticosteroids
19 Recruiting A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Condition: Acute Coronary Syndrome
Interventions: Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
20 Not yet recruiting Effect of Andosan in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Dietary Supplement: Mushroom extract

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years